Loading...
Research Project
Coimbra Chemistry Center
Funder
Authors
Publications
Dextran-Based Injectable Hydrogel Composites for Bone Regeneration
Publication . Alves, Patrícia; Simão, Ana Filipa; Graça, Mariana F. P.; Mariz, Marcos; Correia, I.J.; Ferreira, Paula
Currently, bone infections caused by diseases or injuries are a major health issue. In addition, the conventional therapeutic approaches used to treat bone diseases or injuries present several drawbacks. In the area of tissue engineering, researchers have been developing new alternative therapeutic approaches, such as scaffolds, to promote the regeneration of injured tissues. Despite the advantages of these materials, most of them require an invasive surgical procedure. To overcome these problems, the main focus of this work was to develop scaffolds for bone regeneration, which can be applied using injectable hydrogels that circumvent the use of invasive procedures, while allowing for bone regeneration. Throughout this work, injectable hydrogels were developed based on a natural polymer, dextran, along with the use of two inorganic compounds, calcium β-triphosphate and nanohydroxyapatite, that aimed to reinforce the mechanical properties of the 3D mesh. The materials were chemically characterized considering the requirements for the intended application: the swelling capacity was evaluated, the degradation rate in a simulated physiological environment was assessed, and compression tests were performed. Furthermore, vancomycin was incorporated into the polymeric matrices to obtain scaffolds with antibacterial performance, and their drug release profile was assessed. The cytotoxic profile of the hydrogels was assessed by an MTS assay, using osteoblasts as model cells. The data obtained demonstrated that dextran-based hydrogels were successfully synthesized, with a drug release profile with an initial burst between 50 and 80% of the drug. The hydrogels possess fair biocompatibility. The swelling capacity showed that the stability of the samples and their degradation profile is compatible with the average time period required for bone regeneration (usually about one month) and have a favorable Young’s modulus (200–300 kPa). The obtained hydrogels are well-suited for bone regeneration applications such as infections that occur during implantation or bone graft substitutes with antibiotics.
MicroRNAs-enriched exosomes as a new therapy for Parkinson’s disease
Publication . Esteves, Marta Raquel Carrola; Bernardino, Liliana Inácio; Ferreira, Lino Silva
Parkinson’s disease (PD), a progressive and chronic neurological disorder characterized
by the selective degeneration of the nigrostriatal dopaminergic pathway, has a huge
socioeconomic impact in modern society. Alterations in alpha (α)-synuclein protein
expression and aggregation have been regarded as a primary cause of dopaminergic
neurons death in the substantia nigra (SN) pars compacta. So far, there are no
treatments that halt or reverse the progression of PD. Recent evidence showed that
microRNAs (miRNA), small non-coding RNAs that negatively regulate gene expression,
are dysregulated in PD patients. In particular, miR-124 levels were found decreased in
plasma and postmortem brain parenchyma of PD patients. Thus, miR-124 has become a
relevant molecular therapeutic target for PD. Increasing intracellular levels of miR-124
enhances neurogenesis and neuroprotection in PD models. However, the effect of miR-
124 on α-synuclein dynamics has not yet been reported.
One of the main goals of this thesis was to evaluate the role of miR-124-3p in the
expression and aggregation of α-synuclein protein using the rat model of PD based on
the acute administration of paraquat (PQ). The first research work showed that
intranigral administration of miR-124-3p significantly reduces the protein levels of α-
synuclein and α-synuclein phosphorylated at serine 129 (present in large amounts in
Lewy bodies) in the SN of rats exposed to PQ. Moreover, the protein levels of NADPH
oxidase 1 (Nox1), responsible for the oxidative stress production and eventually involved
in the development of α-synuclein toxicity, and its activator GTPase Rac1, decreased in
SN after miR-124-3p administration in PQ-treated rats. Additionally, the reduced levels
of Pitx3 in the SN caused by the administration of PQ were found to increase after the
administration of miR-124-3p. This work demonstrates for the first time the role of miR-
124-3p in the regulation of α-synuclein toxicity, possibly through the modulation of the
Nox1/Rac1 signaling pathway and in the regulation of Pitx3 expression important for the
survival and maintenance of dopaminergic neurons.
The efficient delivery of miRNA at the intracellular and intracerebral levels has several
limitations since they are highly susceptible to degradation by nucleases and are difficult
to take up by cells due to their negative charge. Recently, several approaches capable of
guaranteeing an efficient delivery of miRNA have been developed. In particular, small
extracellular vesicles (sEV), also referred to as exosomes, have been highlighted as
efficient delivery systems for miRNA due to their intrinsic ability to interact with cells and tissues. The second main goal of this thesis was to use sEV isolated from human
umbilical cord blood-derived mononuclear cells as a biological vehicle of miR-124 and to
evaluate the efficiency of these sEV transfected with miR-124-3p (miR-124-3p sEV) in
inducing neurogenesis and neuroprotection in 6-hydroxydopamine (6-OHDA) PD
model. The second research work showed that in vitro, sEV efficiently deliver miR-124-
3p to subventricular zone (SVZ) neural stem cells (NSC) and to N27 dopaminergic cells.
Treatment of NSC with miR-124-3p sEV induced neuronal differentiation of SVZ NSC
under physiological conditions and protected N27 dopaminergic cells against 6-OHDAinduced
toxicity. In vivo, sEV intracerebroventricularly injected in mice were detected in
SVZ lining the lateral ventricles and in striatum and midbrain sections, the brain regions
most affected by the disease. Although miR-124-3p sEV did not increase the number of
new neurons in the 6-OHDA-lesioned striatum, the formulation protected dopaminergic
neurons in the SN and striatal fibers, which fully counteracted motor behavior symptoms
in mice administered with 6-OHDA.
In conclusion, the results obtained during this thesis provide new evidence on the role of
miR-124-3p in α-synuclein protein pathology and evidence supporting the application of
sEV as biologic delivery agents for miR-124-3p to promote neuroprotection of
dopaminergic neurons. In short, the enrichment of sEV with miR-124-3p may configure
a promising therapeutic strategy able to halt or slow-down dopaminergic neuronal death
in PD.
Photocurable Polymeric Blends for Surgical Application
Publication . Cernadas, Teresa; Santos, Marta; Miguel, Sónia P.; Correia, I.J.; Alves, Patrícia; Ferreira, Paula
The preparation of photocrosslinkable bioadhesives synthesized from oligomers of lactic acid and polycaprolactone (PCL), both functionalized with 2-isocyanoethyl acrylate (AOI), were studied. The obtained modified macromers of LA-AOI (mLA) and PCL-AOI (mCL) were chemically characterized by 1H NMR and used to formulate polymeric blends with different mass proportions, 1:1, 1:2 and 2:1, respectively. Subsequently, the produced blends were crosslinked, considering two UV irradiation times: 30 and 120 s. After their production, the thermal and mechanical properties of bioadhesives were assessed, where upon the rheology, gel content, hydrolytic degradation and dynamic contact angles were determined. Furthermore, the cytotoxic profile of bioadhesives was evaluated in contact with human dermal fibroblasts cells, whereas their antibacterial effect was studied monitoring Escherichia coli and S. aureus growth. Overall, flexible and resistant films were obtained, presenting promising features to be used as surgical bioadhesives.
Organizational Units
Description
Keywords
Contributors
Funders
Funding agency
Fundação para a Ciência e a Tecnologia
Funding programme
6817 - DCRRNI ID
Funding Award Number
UID/QUI/00313/2019